Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17
Figure 5. Europe Digital Biomarkers Market, 2019-2030, $ mn 20
Figure 6. Category and Relationship of Traditional Biomarkers and Digital Biomarkers 21
Figure 7. Benefits and Challenges of Digital Biomarkers 23
Figure 8. Europe Biomarkers Market, 2019-2030, $ mn 24
Figure 9. Share of Digital Biomarkers in Total Biomarkers Market, 2019-2030 24
Figure 10. Impact of COVID-19 on Business 25
Figure 11. Primary Drivers and Impact Factors of Europe Digital Biomarkers Market 27
Figure 12. World 5G Traffic, 2019-2030, EB/year 30
Figure 13. Primary Restraints and Impact Factors of Europe Digital Biomarkers Market 32
Figure 14. Data Security Risk in Various User Groups of Digital Biomarkers 35
Figure 15. Pathway to Regulatory Approval of Digital Biomarkers 36
Figure 16. Investment Opportunity Analysis 38
Figure 17. Porter’s Fiver Forces Analysis of Europe Digital Biomarkers Market 41
Figure 18. Breakdown of Europe Digital Biomarkers Market by System Component, 2019-2030, % of Revenue 46
Figure 19. Europe Addressable Market Cap in 2020-2030 by System Component, Value ($ mn) and Share (%) 46
Figure 20. Europe Digital Biomarkers Market: Data Collection Tools, 2019-2030, $ mn 47
Figure 21. Europe Digital Biomarkers Market: Digital Platforms, 2019-2030, $ mn 49
Figure 22. Europe Digital Biomarkers Market: Mobile Apps, 2019-2030, $ mn 50
Figure 23. Europe Digital Biomarkers Market: Desktop-based Software, 2019-2030, $ mn 51
Figure 24. Europe Digital Biomarkers Market: Wearables, 2019-2030, $ mn 52
Figure 25. Europe Digital Biomarkers Market: Biosensors, 2019-2030, $ mn 53
Figure 26. Europe Digital Biomarkers Market: Data Integration Systems, 2019-2030, $ mn 54
Figure 27. Breakdown of Europe Digital Biomarkers Market by Therapeutic Area, 2019-2030, % of Sales Revenue 56
Figure 28. Europe Addressable Market Cap in 2020-2030 by Therapeutic Area, Value ($ mn) and Share (%) 56
Figure 29. Europe Digital Biomarkers Market: Cardiovascular Diseases, 2019-2030, $ mn 57
Figure 30. Europe Digital Biomarkers Market: Neurodegenerative Disorders, 2019-2030, $ mn 58
Figure 31. Europe Digital Biomarkers Market: Parkinson’s Disease, 2019-2030, $ mn 60
Figure 32. Europe Digital Biomarkers Market: Multiple Sclerosis, 2019-2030, $ mn 61
Figure 33. Europe Digital Biomarkers Market: Alzheimer’s Disease, 2019-2030, $ mn 62
Figure 34. Europe Digital Biomarkers Market: Sleep and Movement Diseases, 2019-2030, $ mn 63
Figure 35. Europe Digital Biomarkers Market: Psychiatric Disorders, 2019-2030, $ mn 64
Figure 36. Europe Digital Biomarkers Market: Chronic Pain, 2019-2030, $ mn 65
Figure 37. Europe Digital Biomarkers Market: Gastrointestinal Diseases, 2019-2030, $ mn 66
Figure 38. Europe Digital Biomarkers Market: Diabetes, 2019-2030, $ mn 67
Figure 39. Europe Digital Biomarkers Market: Respiratory Conditions, 2019-2030, $ mn 68
Figure 40. Europe Digital Biomarkers Market: Other Diseases, 2019-2030, $ mn 69
Figure 41. Breakdown of Europe Digital Biomarkers Market by Application, 2019-2030, % of Sales Revenue 71
Figure 42. Europe Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%) 71
Figure 43. Europe Digital Biomarkers Market: Wellness, 2019-2030, $ mn 72
Figure 44. Europe Digital Biomarkers Market: Disease Diagnosis, 2019-2030, $ mn 73
Figure 45. Europe Digital Biomarkers Market: Personalised Medication, 2019-2030, $ mn 74
Figure 46. Europe Digital Biomarkers Market: Drug Discovery and Development, 2019-2030, $ mn 75
Figure 47. Classification of Digital Biomarkers by Development Status 77
Figure 48. Breakdown of Europe Digital Biomarkers Market by Development Status, 2019-2030, % of Revenue 79
Figure 49. Europe Addressable Market Cap in 2020-2030 by Development Status, Value ($ mn) and Share (%) 79
Figure 50. Europe Digital Biomarkers Market: Novel Digital Biomarkers, 2019-2030, $ mn 80
Figure 51. Europe Digital Biomarkers Market: Original Digital Biomarkers, 2019-2030, $ mn 81
Figure 52. Europe Digital Biomarkers Market: Approved Digital Biomarkers, 2019-2030, $ mn 82
Figure 53. Breakdown of Europe Digital Biomarkers Market by End User, 2019-2030, % of Revenue 84
Figure 54. Europe Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%) 84
Figure 55. Europe Digital Biomarkers Market: Biopharmaceutical Companies & Labs, 2019-2030, $ mn 85
Figure 56. Europe Digital Biomarkers Market: Healthcare Providers, 2019-2030, $ mn 86
Figure 57. Europe Digital Biomarkers Market: Insurance Payers, 2019-2030, $ mn 87
Figure 58. Breakdown of European Digital Biomarkers Market by Country, 2019 and 2030, % of Revenue 89
Figure 59. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 90
Figure 60. Digital Biomarkers Market in Germany, 2019-2030, $ mn 91
Figure 61. Digital Biomarkers Market in UK, 2019-2030, $ mn 93
Figure 62. Digital Biomarkers Market in France, 2019-2030, $ mn 95
Figure 63. Digital Biomarkers Market in Netherlands, 2019-2030, $ mn 97
Figure 64. Digital Biomarkers Market in Italy, 2019-2030, $ mn 99
Figure 65. Digital Biomarkers Market in Russia, 2019-2030, $ mn 101
Figure 66. Digital Biomarkers Market in Rest of Europe, 2019-2030, $ mn 103
Figure 67. Growth Stage of Europe Digital Biomarkers Industry over the Forecast Period 105
Europe digital biomarkers market accounted for $118.0 million in 2019 and will grow by 40.3% annually over 2020-2030 owing to the rising demand for mobile health apps, elevated level of smartphone and wearable technology in healthcare amid COVID-19 epidemic. Highlighted with 42 tables and 67 figures, this 145-page report “Europe Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe digital biomarkers market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe digital biomarkers market in every aspect of the classification from perspectives of System Component, Therapeutic Area, Application, Development Status, End User, and Country. Based on System Component, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Data Collection Tools • Digital Platforms • Mobile Apps • Desktop-based Software • Wearables • Biosensors Data Integration Systems Based on Therapeutic Area, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Cardiovascular Diseases Neurodegenerative Disorders • Parkinson’s Disease • Multiple Sclerosis • Alzheimer’s Disease Sleep and Movement Diseases Psychiatric Disorders Chronic Pain Gastrointestinal Diseases Diabetes Respiratory Conditions Other Diseases Based on Application, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Wellness • Disease Diagnosis • Personalised Medication • Drug Discovery and Development Based on Development Status, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Novel Digital Biomarkers • Original Digital Biomarkers • Approved Digital Biomarkers Based on End User, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Biopharmaceutical Companies & Labs • Healthcare Providers • Insurance Payers Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Netherlands • Italy • Russia • Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, Spain, Poland, Czech Republic, Slovakia, Hungary, and Romania) For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by System Component, Therapeutic Area, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Europe digital biomarkers market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Actigraph LLC Akili Interactive Labs AliveCor Inc Altoida Inc Amgen Inc Bayer AG Biogen Inc Cambridge Cognition Plc Eli Lilly and Company Evidation Health, Inc. F. Hoffmann-La Roche Ltd Fitbit Inc GlaxoSmithKline Plc Happify Health Human API IXICO Plc Koninklijke Philips N.V. Medical Care Corporation Medopad Ltd Mindstrong Health Neurotrack Technology, Inc Novartis International AG Pfizer Inc. Quanterix Corporation Sanofi S.A. The Takeda Pharmaceuticals Company Limited Verily Life Sciences Winterlight Labs Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More